文献速递淋巴瘤

生物类似药CT-P10与利妥昔单抗初治晚期滤泡性淋巴瘤的疗效、药代动力学与安全性比较:随机双盲平行组非劣效3期试验

Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 compared with rituximab in patients with previously untreated advanced-stage follicular lymphoma: a randomised, double-blind, parallel-group, non-inferiority phase 3 trial.
PubMed 文献 · Lancet Haematol · 2017-07-14

这项正在进行的随机双盲平行组3期试验将140例初治晚期滤泡性淋巴瘤患者按1:1分配接受CVP联合CT-P10或利妥昔单抗治疗8个周期。CT-P10组总缓解率为97.0%(64/66),利妥昔单抗组为92.6%(63/68),非劣效性成立;AUCτ与CmaxSS的几何均值比90%置信区间均在80%-125%等效界内。两组安全性相当。

要点

  • CT-P10组总缓解率97.0%(64/66) vs 利妥昔单抗组92.6%(63/68),非劣效性成立。
  • AUCτ几何均值比102.25%(90%CI 94.05-111.17),CmaxSS为100.67%(93.84-108.00),均在等效界内。
  • 两组治疗中出现的不良事件发生率分别为83%与80%,安全性相当。

核心结论

  • CT-P10表现出与利妥昔单抗非劣效的疗效和药代动力学等效性,安全性特征相当,可能成为晚期滤泡性淋巴瘤的新治疗选择。

研究设计与样本

  • 正在进行的随机、双盲、平行组、阳性对照3期研究,纳入140例18岁及以上Ann Arbor III-IV期滤泡性淋巴瘤初治患者。
  • 患者按1:1随机分配至CVP联合375 mg/m2 CT-P10或利妥昔单抗组,于8个21天周期的第1天静脉输注。
  • 随机化按国家、性别和滤泡性淋巴瘤国际预后指数评分(0-2 vs 3-5)分层,采用置换区组平衡。
  • 研究分为两部分:第1部分在药代动力学亚组评估药代动力学等效性,第2部分在所有随机患者中评估疗效。

主要发现

  • 疗效人群中CT-P10组总缓解率为97.0%(64/66),利妥昔单抗组为92.6%(63/68),差值4.3%(单侧97.5%CI -4.25),位于预定义非劣效界-7%的正侧。
  • AUCτ的几何最小二乘均值比(CT-P10/利妥昔单抗)为102.25%(90%CI 94.05-111.17),CmaxSS为100.67%(90%CI 93.84-108.00),所有置信区间均在80%-125%等效界内。
  • 治疗中出现的不良事件在CT-P10组报告于83%(58/70)患者,利妥昔单抗组为80%(56/70)。
  • 最常见的3或4级治疗中出现不良事件为中性粒细胞减少:CT-P10组3级15例(21%,15/70),利妥昔单抗组7例(10%,7/70)。
  • 至少发生一次治疗中出现严重不良事件的患者比例:CT-P10组23%(16/70),利妥昔单抗组13%(9/70)。

关键数值与推荐

  • 药代动力学等效性标准:AUCτ和CmaxSS的几何均值比90%CI均在80%-125%等效界内。
  • 疗效非劣效性标准:单侧97.5%CI位于-7%非劣效界的正侧,采用2.5%显著性水平的单侧检验。
  • 主要疗效终点:8个周期内的总缓解率,在疗效人群(所有随机患者)中评估。
  • 主要药代动力学终点:第4周期稳态血清浓度-时间曲线下面积(AUCτ)和稳态最大血清浓度(CmaxSS),在药代动力学人群中评估。

临床怎么用

  • 作者认为CT-P10可能代表晚期滤泡性淋巴瘤的一种新治疗选择。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Studies in patients with rheumatoid arthritis have shown that the rituximab biosimilar CT-P10 (Celltrion, Incheon, South Korea) has equivalent efficacy and pharmacokinetics to rituximab. In this phase 3 study, we aimed to assess the non-inferior efficacy and pharmacokinetic equivalence of CT-P10 compared with rituximab, when used in combination with cyclophosphamide, vincristine, and prednisone (CVP) in patients with newly diagnosed advanced-stage follicular lymphoma. METHODS: In this ongoing, randomised, double-blind, parallel-group, active-controlled study, patients aged 18 years or older with Ann Arbor stage III-IV follicular lymphoma were assigned 1:1 to CVP plus intravenous infusions of 375 mg/m2 CT-P10 or rituximab on day 1 of eight 21-day cycles. Randomisation was done by the investigators using an interactive web or voice response system and a computer-generated randomisation schedule, prepared by a clinical research organisation. Randomisation was balanced using permuted blocks and was stratified by country, gender, and Follicular Lymphoma International Prognostic Index score (0-2 vs 3-5). Study teams from the sponsor and clinical research organisation, investigators, and patients were masked to treatment assignment. The study was divided into two parts: part 1 assessing equivalence of pharmacokinetics (in the pharmacokinetics subset), and part 2 assessing efficacy in all randomised patients (patients from the pharmacokinetics subset plus additional patients enrolled in part 2). Equivalence of pharmacokinetics was shown if the 90% CIs for the geometric mean ratio of CT-P10 to rituximab in AUCτ and CmaxSS were within the bounds of the equivalence margin of 80% and 125%. Non-inferiority of response was shown if the one-sided 97·5% CI lay on the positive side of the -7% margin, using a one-sided test done at the 2·5% significance level. The primary efficacy endpoint was the proportion of patients who had an overall response over eight cycles and was assessed in the efficacy population (all randomised patients). The primary pharmacokinetic endpoints were area under the serum concentration-time curve at steady state (AUCτ) and maximum serum concentration at steady state (CmaxSS) at cycle 4, assessed in the pharmokinetic population. This trial is registered with ClinicalTrials.gov, number NCT02162771. FINDINGS: Between July 28, 2014, and Dec 29, 2015, 140 patients were enrolled. Here we report data for the eight-cycle induction period, up to week 24. The proportion of patients with an overall response in the efficacy population was 64 (97·0%) of 66 patients in the CT-P10 treatment group and 63 (92·6%) of 68 patients in the rituximab treatment group (4·3%; one-sided 97·5% CI -4·25), which lay on the positive side of the predefined non-inferiority margin. The ratio of geometric least squares means (CT-P10/rituximab) was 102·25% (90% CI 94·05-111·17) for AUCτ and 100·67% (93·84-108·00) for CmaxSS, with all CIs within the bioequivalence margin of 80-125%. Treatment-emergent adverse events were reported for 58 (83%) of 70 patients in the CT-P10 treatment group and 56 (80%) of 70 in the rituximab treatment group. The most common grade 3 or 4 treatment-emergent adverse event in each treatment group was neutropenia (grade 3, 15 [21%] of 70 patients in the CT-P10 group and seven [10%] of 70 patients in the rituximab group). The proportion of patients who experienced at least one treatment-emergent serious adverse event was 16 (23%) of 70 patients in the CT-P10 group and nine (13%) of 70 patients in the rituximab group. INTERPRETATION: In this study, we show that CT-P10 exhibits non-inferior efficacy and pharmacokinetic equivalence to rituximab. The safety profile of CT-P10 was comparable to that of rituximab. CT-P10 might represent a new therapeutic option for advanced-stage follicular lymphoma. FUNDING: Celltrion, Inc.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. Kim WS, Buske C, Ogura M, et al. Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 compared with rituximab in patients with previously untreated advanced-stage follicular lymphoma: a randomised, double-blind, parallel-group, non-inferiority phase 3 trial. Lancet Haematol. 2017. PMID: 28712940. doi:10.1016/S2352-3026(17)30120-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。